PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
17316566-7	2007	Naive T cells co-cultured with Sugiol-primed DC, turned into typical Th2 which produced large quantities of IL-4 and released small amounts of IFN-gamma and reduced Th1 cell polarizing capacity.	sugiol	31-37	interleukin 4	Homo sapiens	108-112
26212545-0	2015	Sugiol inhibits STAT3 activity via regulation of transketolase and ROS-mediated ERK activation in DU145 prostate carcinoma cells.	sugiol	0-6	signal transducer and activator of transcription 3	Homo sapiens	16-21
26212545-0	2015	Sugiol inhibits STAT3 activity via regulation of transketolase and ROS-mediated ERK activation in DU145 prostate carcinoma cells.	sugiol	0-6	transketolase	Homo sapiens	49-62
26212545-0	2015	Sugiol inhibits STAT3 activity via regulation of transketolase and ROS-mediated ERK activation in DU145 prostate carcinoma cells.	sugiol	0-6	mitogen-activated protein kinase 1	Homo sapiens	80-83
26212545-4	2015	Sugiol specifically inhibited STAT3 phosphorylation at Tyr-705 in DU145 prostate cells, and this inhibition was independent of the STAT3 upstream kinase.	sugiol	0-6	signal transducer and activator of transcription 3	Homo sapiens	30-35
26212545-5	2015	Sugiol induced cell cycle arrest and decreased the expression levels of STAT3 target genes, such as cyclin D1, cyclin A, and survivin.	sugiol	0-6	signal transducer and activator of transcription 3	Homo sapiens	72-77
26212545-5	2015	Sugiol induced cell cycle arrest and decreased the expression levels of STAT3 target genes, such as cyclin D1, cyclin A, and survivin.	sugiol	0-6	cyclin D1	Homo sapiens	100-109
26212545-5	2015	Sugiol induced cell cycle arrest and decreased the expression levels of STAT3 target genes, such as cyclin D1, cyclin A, and survivin.	sugiol	0-6	cyclin A2	Homo sapiens	111-119
26212545-6	2015	Notably, we observed that sugiol interacted with transketolase, an enzyme in central metabolism, and increased ROS levels leading to the activation of ERK, which inhibits STAT3 activity.	sugiol	26-32	transketolase	Homo sapiens	49-62
26212545-6	2015	Notably, we observed that sugiol interacted with transketolase, an enzyme in central metabolism, and increased ROS levels leading to the activation of ERK, which inhibits STAT3 activity.	sugiol	26-32	mitogen-activated protein kinase 1	Homo sapiens	151-154
26212545-6	2015	Notably, we observed that sugiol interacted with transketolase, an enzyme in central metabolism, and increased ROS levels leading to the activation of ERK, which inhibits STAT3 activity.	sugiol	26-32	signal transducer and activator of transcription 3	Homo sapiens	171-176
26212545-7	2015	The protein phosphatase MEG2 was also responsible for sugiol-induced STAT3 dephosphorylation.	sugiol	54-60	protein tyrosine phosphatase non-receptor type 9	Homo sapiens	24-28
26212545-7	2015	The protein phosphatase MEG2 was also responsible for sugiol-induced STAT3 dephosphorylation.	sugiol	54-60	signal transducer and activator of transcription 3	Homo sapiens	69-74
26212545-9	2015	We propose that sugiol inhibits STAT3 activity through a mechanism that involves the inhibition of transketolase, which leads to increased ROS levels and MEG2 activation in DU145 cells.	sugiol	16-22	signal transducer and activator of transcription 3	Homo sapiens	32-37
26212545-9	2015	We propose that sugiol inhibits STAT3 activity through a mechanism that involves the inhibition of transketolase, which leads to increased ROS levels and MEG2 activation in DU145 cells.	sugiol	16-22	transketolase	Homo sapiens	99-112
26212545-9	2015	We propose that sugiol inhibits STAT3 activity through a mechanism that involves the inhibition of transketolase, which leads to increased ROS levels and MEG2 activation in DU145 cells.	sugiol	16-22	protein tyrosine phosphatase non-receptor type 9	Homo sapiens	154-158
26212545-10	2015	Therefore, sugiol is the first compound regulating STAT3 activity via modulation of cancer metabolic pathway and we suggest the use of sugiol as an inhibitor of the STAT3 pathway for the treatment of human solid tumors with activated STAT3.	sugiol	11-17	signal transducer and activator of transcription 3	Homo sapiens	51-56
17316566-7	2007	Naive T cells co-cultured with Sugiol-primed DC, turned into typical Th2 which produced large quantities of IL-4 and released small amounts of IFN-gamma and reduced Th1 cell polarizing capacity.	sugiol	31-37	interferon gamma	Homo sapiens	143-152
17316566-7	2007	Naive T cells co-cultured with Sugiol-primed DC, turned into typical Th2 which produced large quantities of IL-4 and released small amounts of IFN-gamma and reduced Th1 cell polarizing capacity.	sugiol	31-37	negative elongation factor complex member C/D	Homo sapiens	165-168
17316566-8	2007	Sugiol-primed DC induced the development of Th2 cells via the enhanced expression of OX40L and augmented the Th2 cell polarizing capacity of DC via the inhibition of IL-12p70.	sugiol	0-6	TNF superfamily member 4	Homo sapiens	85-90
32190154-0	2020	Anticancer activity of sugiol against ovarian cancer cell line SKOV3 involves mitochondrial apoptosis, cell cycle arrest and blocking of the RAF/MEK/ERK signalling pathway.	sugiol	23-29	zinc fingers and homeoboxes 2	Homo sapiens	141-144
33968578-7	2021	Sugiol also triggered increase in Bax and decrease in Bcl-2 expression.	sugiol	0-6	BCL2 associated X, apoptosis regulator	Homo sapiens	34-37
33968578-7	2021	Sugiol also triggered increase in Bax and decrease in Bcl-2 expression.	sugiol	0-6	BCL2 apoptosis regulator	Homo sapiens	54-59
15856404-5	2005	Moreover, sugiol reveals a capacity for suppressing the activation of mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38 mitogen-activated protein kinase (p38) activated by LPS-stimulation in J774A.1 murine macrophages.	sugiol	10-16	mitogen-activated protein kinase 1	Mus musculus	123-160
15856404-5	2005	Moreover, sugiol reveals a capacity for suppressing the activation of mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38 mitogen-activated protein kinase (p38) activated by LPS-stimulation in J774A.1 murine macrophages.	sugiol	10-16	mitogen-activated protein kinase 1	Mus musculus	162-165
15856404-5	2005	Moreover, sugiol reveals a capacity for suppressing the activation of mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38 mitogen-activated protein kinase (p38) activated by LPS-stimulation in J774A.1 murine macrophages.	sugiol	10-16	mitogen-activated protein kinase 8	Mus musculus	168-193
15856404-5	2005	Moreover, sugiol reveals a capacity for suppressing the activation of mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38 mitogen-activated protein kinase (p38) activated by LPS-stimulation in J774A.1 murine macrophages.	sugiol	10-16	mitogen-activated protein kinase 8	Mus musculus	195-198
15856404-5	2005	Moreover, sugiol reveals a capacity for suppressing the activation of mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38 mitogen-activated protein kinase (p38) activated by LPS-stimulation in J774A.1 murine macrophages.	sugiol	10-16	mitogen-activated protein kinase 14	Mus musculus	205-208
15856404-5	2005	Moreover, sugiol reveals a capacity for suppressing the activation of mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38 mitogen-activated protein kinase (p38) activated by LPS-stimulation in J774A.1 murine macrophages.	sugiol	10-16	mitogen-activated protein kinase 14	Mus musculus	243-246
15856404-6	2005	A low dosage of 10 microM of sugiol completely inhibited ERK1/2 phosphorylation, while 30 microM effectively inhibited JNK1/2 and p38 phosphorylation in LPS-stimulated macrophages.	sugiol	29-35	mitogen-activated protein kinase 14	Mus musculus	130-133
29552785-9	2018	Additionally, sugiol caused cell cycle arrest in G2/M phase of the cell cycle and upregulated the expression of Bax, with concomitant downregulation of Bcl-2 expression in comparison to the untreated cells.	sugiol	14-20	BCL2 associated X, apoptosis regulator	Homo sapiens	112-115
29552785-9	2018	Additionally, sugiol caused cell cycle arrest in G2/M phase of the cell cycle and upregulated the expression of Bax, with concomitant downregulation of Bcl-2 expression in comparison to the untreated cells.	sugiol	14-20	BCL2 apoptosis regulator	Homo sapiens	152-157
32190154-0	2020	Anticancer activity of sugiol against ovarian cancer cell line SKOV3 involves mitochondrial apoptosis, cell cycle arrest and blocking of the RAF/MEK/ERK signalling pathway.	sugiol	23-29	mitogen-activated protein kinase kinase 7	Homo sapiens	145-148
32190154-0	2020	Anticancer activity of sugiol against ovarian cancer cell line SKOV3 involves mitochondrial apoptosis, cell cycle arrest and blocking of the RAF/MEK/ERK signalling pathway.	sugiol	23-29	mitogen-activated protein kinase 1	Homo sapiens	149-152
32190154-15	2020	Moreover, the results showed that sugiol could inhibit the RAF/MEK/ERK signalling pathway in a dose-dependent manner.	sugiol	34-40	zinc fingers and homeoboxes 2	Homo sapiens	59-62
32190154-15	2020	Moreover, the results showed that sugiol could inhibit the RAF/MEK/ERK signalling pathway in a dose-dependent manner.	sugiol	34-40	mitogen-activated protein kinase kinase 7	Homo sapiens	63-66
32190154-15	2020	Moreover, the results showed that sugiol could inhibit the RAF/MEK/ERK signalling pathway in a dose-dependent manner.	sugiol	34-40	mitogen-activated protein kinase 1	Homo sapiens	67-70
32190154-16	2020	Conclusions: The results of the present study indicate that sugiol exerts potent anticancer effects on SKOV3 cells via induction of cell cycle arrest, mitochondrial apoptosis and inhibition of the RAF/MEK/ERK signalling pathway.	sugiol	60-66	zinc fingers and homeoboxes 2	Homo sapiens	197-200
32190154-16	2020	Conclusions: The results of the present study indicate that sugiol exerts potent anticancer effects on SKOV3 cells via induction of cell cycle arrest, mitochondrial apoptosis and inhibition of the RAF/MEK/ERK signalling pathway.	sugiol	60-66	mitogen-activated protein kinase kinase 7	Homo sapiens	201-204
32190154-16	2020	Conclusions: The results of the present study indicate that sugiol exerts potent anticancer effects on SKOV3 cells via induction of cell cycle arrest, mitochondrial apoptosis and inhibition of the RAF/MEK/ERK signalling pathway.	sugiol	60-66	mitogen-activated protein kinase 1	Homo sapiens	205-208